Advertisement
ALLO vs AXON
Which Stock Would AI Choose? Allogene Therapeutics (ALLO) vs. Axon Enterprise (AXON) Stock Comparison
Key Takeaways
- Allogene Therapeutics (ALLO) is a clinical-stage biotech with no marketed product, while Axon Enterprise (AXON) is a profitable public-safety technology leader with rapid revenue growth.
- ALLO's near-term story hinges on clinical trial catalysts, particularly the ALPHA3 study and a fourth-quarter 2026 data update for its autoimmune program.
- AXON delivered roughly 34–35% year-over-year revenue growth in recent quarters but has seen its share price decline significantly from 2025 highs as high-valuation growth stocks repriced.
- The two names sit at opposite ends of the risk spectrum: ALLO offers binary, catalyst-driven upside, while AXON offers established cash flow with premium valuation.
- Get more detail on each ticker's major news and daily price action on dedicated pages: ALLO Major News and ALLO Today's Price Move, as well as AXON Major News and AXON Today's Price Move.
- To see how AI-powered trading systems are currently positioning across the market, explore Trending AI Robots.
Introduction
Comparing ALLO and AXON places two fundamentally different investment profiles side by side. Allogene Therapeutics is a clinical-stage immuno-oncology company developing "off-the-shelf" allogeneic CAR T cell therapies (engineered immune cells from healthy donors), while Axon Enterprise builds TASER devices, body cameras, software, and AI tools for law enforcement and public safety. This stock comparison is relevant to investors weighing high-growth, cash-generating businesses against speculative, catalyst-driven biotech — and to traders assessing how relative performance and market positioning shift across sectors with very different risk-reward dynamics.
ALLO Overview and Recent Performance
Allogene Therapeutics is a South San Francisco-based biotech that has not yet commercialized a product, meaning its equity value is driven primarily by clinical data and cash position rather than revenue. Recent market activity has reflected encouraging but still preliminary trial results. In its ALPHA3 pivotal study of lead candidate cema-cel in large B-cell lymphoma (LBCL), an interim futility analysis showed a 58.3% minimal residual disease (MRD) negativity rate at day 45 versus 16.7% for observation, with no treatment-related serious adverse events reported.
The company completed a public offering generating roughly $200 million in gross proceeds, extending its cash runway into 2029. Shares have risen substantially on a year-to-date basis yet remain volatile, with elevated short interest and a beta above the broader market. A fourth-quarter 2026 update on the ALLO-329 autoimmune program is a key near-term catalyst, while definitive event-free survival (EFS) data is not expected until 2027–2028. These factors make ALLO's relative performance highly sensitive to binary clinical outcomes.
AXON Overview and Recent Performance
Axon Enterprise is a founder-led public-safety technology company whose ecosystem spans TASER energy weapons, body-worn and in-car cameras, drones, digital evidence management, and AI-driven software. The business has delivered strong fundamentals, with quarterly revenue growing roughly 34–35% year over year and its AI Era product line expanding rapidly. Future contracted bookings and a high net revenue retention rate underscore recurring revenue strength.
Despite this, AXON's stock has been a notable laggard over the past year, falling well below its 2025 all-time high as richly valued growth and software names repriced amid a broader pullback in high-multiple equities. The company recently unveiled its Axon Body 5 camera at the 2026 IACP conference, and analysts maintain a predominantly Buy consensus with an average price target above recent trading levels. The stock's forward valuation remains elevated, keeping sentiment sensitive to growth durability and margin execution.
Trending AI Robots
Tickeron maintains a curated Trending AI Robots section that highlights a selection of AI trading bots from a library of hundreds, which collectively trade thousands of different tickers. Because not every bot suits every market regime, only those best aligned with current conditions earn a place in this shortlist. The bots vary widely in trading style, strategy, timeframe, performance metrics, and the tickers they cover — from momentum and swing strategies to longer-horizon approaches. For investors comparing names like ALLO and AXON, this provides a data-driven lens on how automated systems are positioning across market conditions. Explore Trending AI Robots to review the currently featured strategies and their statistics.
Head-to-Head Comparison
The clearest contrast between these two stocks is business maturity. AXON generates billions in annual revenue, positive net income, and a growing recurring software base; ALLO generates essentially no product sales and depends on capital raises and clinical milestones. Consequently, their risk profiles diverge sharply: AXON's risks center on valuation compression, government budget cycles, and margin pressure from newer hardware lines, while ALLO's risks center on binary trial outcomes and dilution.
On momentum, the two have recently moved in opposite directions on a trailing basis — ALLO has posted strong year-to-date gains on trial optimism, while AXON has underperformed despite robust fundamentals. Sentiment also differs: AXON enjoys broad analyst coverage and a Buy consensus, whereas ALLO faces meaningful short interest and split analyst views. For sector exposure, AXON offers defensive, recurring-revenue public-safety technology, while ALLO offers speculative exposure to next-generation cell therapy and autoimmune disease.
Tickeron AI Verdict
Based on observable factors such as trend consistency, stability, and catalyst structure, Tickeron's AI would likely favor AXON as the more consistent, lower-volatility holding, given its established revenue base, recurring cash flows, and durable business model — even as its share price has corrected. ALLO presents a more speculative, catalyst-dependent profile; its positioning improves around clinical data events, but its trend is less stable and more sensitive to binary outcomes. The verdict is probabilistic rather than definitive, reflecting the fundamentally different risk-reward trade-offs each stock offers.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is ALLO is a Hold and AXON is a Hold.
ALLO in -15.09% downward trend, sliding for three consecutive days on November 11, 2026
Moving lower for three straight days is viewed as a bearish sign. Keep an eye on this stock for future declines. Considering data from situations where ALLO declined for three days, in 283 of 312 cases, the price declined further within the following month. The odds of a continued downward trend are 90%.
Technical Analysis (Indicators)
Bearish Trend Analysis
The Momentum Indicator moved below the 0 level on October 29, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on ALLO as a result. In 73 of 83 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 88%.
The Moving Average Convergence Divergence Histogram (MACD) for ALLO turned negative on November 06, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 47 similar instances when the indicator turned negative. In 41 of the 47 cases the stock turned lower in the days that followed. This puts the odds of success at 87%.
The Aroon Indicator for ALLO entered a downward trend on November 11, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Bullish Trend Analysis
The RSI Indicator demonstrates that the ticker has stayed in the oversold zone for 1 day, which means it's wise to expect a price bounce in the near future.
The Stochastic Oscillator shows that the ticker has stayed in the oversold zone for 7 days. The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an upward trend is expected.
Following a +9.17% 3-day Advance, the price is estimated to grow further. Considering data from situations where ALLO advanced for three days, in 185 of 228 cases, the price rose further within the following month. The odds of a continued upward trend are 81%.
ALLO may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
Fundamental Analysis (Ratings)
The Tickeron PE Growth Rating for this company is 12 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Valuation Rating of 48 (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (0.824) is normal, around the industry mean (3.498). P/E Ratio (-1.576) is within average values for comparable stocks, (-1.193). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (130.981) among similar stocks. P/S Ratio (91.743) is also within normal values, averaging (440.869).
The Tickeron Price Growth Rating for this company is 88 (best 1 - 100 worst), indicating slightly worse than average price growth. ALLO’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron SMR rating for this company is 97 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. ALLO’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 93, placing this stock worse than average.
AXON's Indicator enters downward trend
The Aroon Indicator for AXON entered a downward trend on October 28, 2026. Tickeron's A.I.dvisor identified a pattern where the AroonDown red line was above 70 while the AroonUp green line was below 30 for three straight days. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options. A.I.dvisor looked at 117 similar instances where the Aroon Indicator formed such a pattern. In 96 of the 117 cases the stock moved lower. This puts the odds of a downward move at 82%.
Technical Analysis (Indicators)
Bearish Trend Analysis
The Momentum Indicator moved below the 0 level on November 05, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on AXON as a result. In 52 of 75 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 69%.
The Moving Average Convergence Divergence Histogram (MACD) for AXON turned negative on November 06, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 38 similar instances when the indicator turned negative. In 31 of the 38 cases the stock turned lower in the days that followed. This puts the odds of success at 82%.
The 50-day moving average for AXON moved below the 200-day moving average on October 23, 2026. This could be a long-term bearish signal for the stock as the stock shifts to an downward trend.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where AXON declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 70%.
Bullish Trend Analysis
The RSI Indicator shows that the ticker has stayed in the oversold zone for 3 days. The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an Uptrend is expected.
The Stochastic Oscillator shows that the ticker has stayed in the oversold zone for 3 days. The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an upward trend is expected.
Following a +1.31% 3-day Advance, the price is estimated to grow further. Considering data from situations where AXON advanced for three days, in 273 of 370 cases, the price rose further within the following month. The odds of a continued upward trend are 74%.
AXON may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
Fundamental Analysis (Ratings)
The Tickeron Price Growth Rating for this company is 65 (best 1 - 100 worst), indicating fairly steady price growth. AXON’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron PE Growth Rating for this company is 80 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron SMR rating for this company is 81 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 82 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. AXON’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 78, placing this stock worse than average.
The Tickeron Valuation Rating of 90 (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (6.920) is normal, around the industry mean (5.050). AXON has a moderately high P/E Ratio (126.721) as compared to the industry average of (17.247). Projected Growth (PEG Ratio) (1.949) is also within normal values, averaging (3.110). Dividend Yield (0.000) settles around the average of (0.055) among similar stocks. P/S Ratio (12.034) is also within normal values, averaging (18.367).
ALLO | AXON | ||
|---|---|---|---|
OUTLOOK RATING 1..100 | 16 | 56 | |
VALUATION overvalued / fair valued / undervalued 1..100 | 48 Fair valued | 90 Overvalued | |
PROFIT vs RISK RATING 1..100 | 100 | 82 | |
SMR RATING 1..100 | 97 | 81 | |
PRICE GROWTH RATING 1..100 | 88 | 65 | |
P/E GROWTH RATING 1..100 | 12 | 80 | |
SEASONALITY SCORE 1..100 | 50 | 43 |
Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.
ALLO's Valuation (48) in the Biotechnology industry is somewhat better than the same rating for AXON (90). This means that ALLO’s stock grew somewhat faster than AXON’s over the last 12 months.
AXON's Profit vs Risk Rating (82) in the Biotechnology industry is in the same range as ALLO (100). This means that AXON’s stock grew similarly to ALLO’s over the last 12 months.
AXON's SMR Rating (81) in the Biotechnology industry is in the same range as ALLO (97). This means that AXON’s stock grew similarly to ALLO’s over the last 12 months.
AXON's Price Growth Rating (65) in the Biotechnology industry is in the same range as ALLO (88). This means that AXON’s stock grew similarly to ALLO’s over the last 12 months.
ALLO's P/E Growth Rating (12) in the Biotechnology industry is significantly better than the same rating for AXON (80). This means that ALLO’s stock grew significantly faster than AXON’s over the last 12 months.
| ALLO | AXON | |
|---|---|---|
| RSI ODDS (%) | 2 days ago 86% | 2 days ago 82% |
| Stochastic ODDS (%) | 2 days ago 88% | 2 days ago 84% |
| Momentum ODDS (%) | 2 days ago 88% | 2 days ago 69% |
| MACD ODDS (%) | 2 days ago 87% | 2 days ago 82% |
| TrendWeek ODDS (%) | 2 days ago 90% | 2 days ago 69% |
| TrendMonth ODDS (%) | 2 days ago 90% | 2 days ago 71% |
| Advances ODDS (%) | 9 days ago 81% | 17 days ago 74% |
| Declines ODDS (%) | 2 days ago 90% | 3 days ago 70% |
| BollingerBands ODDS (%) | 2 days ago 82% | 2 days ago 85% |
| Aroon ODDS (%) | 2 days ago 89% | 2 days ago 82% |
Long-Term Analysis
It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is overvalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).
ALLO’s FA Score shows that 1 FA rating(s) are green while AXON’s FA Score has 0 green FA rating(s).
- ALLO’s FA Score: 1 green, 4 red.
- AXON’s FA Score: 0 green, 5 red.
Short-Term Analysis
It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.
If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.
ALLO’s TA Score shows that 4 TA indicator(s) are bullish while AXON’s TA Score has 4 bullish TA indicator(s).
- ALLO’s TA Score: 4 bullish, 4 bearish.
- AXON’s TA Score: 4 bullish, 5 bearish.
Price Growth
ALLO (@Biotechnology) experienced а -24.36% price change this week, while AXON (@Aerospace & Defense) price change was -25.64% for the same time period.
The average weekly price growth across all stocks in the @Biotechnology industry was +11.66%. For the same industry, the average monthly price growth was +1.65%, and the average quarterly price growth was -13.40%.
The average weekly price growth across all stocks in the @Aerospace & Defense industry was +12.32%. For the same industry, the average monthly price growth was +0.48%, and the average quarterly price growth was -12.77%.
Reported Earning Dates
ALLO is expected to report earnings on Mar 18, 2027.
AXON is expected to report earnings on Mar 02, 2027.
Industries' Descriptions
@Biotechnology (+11.66% weekly)Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.
@Aerospace & Defense (+12.32% weekly)Aerospace & Defense is one of largest industries in the U.S., mainly comprising the following areas: commercial airliners, military aircraft, missiles, space, and general aviation. Focused heavily on research & development, it is also one of the fastest growing industries. Military aircraft has the largest market share in the industry’s sales, followed by space systems, civil aircraft, and missiles. Aerospace exports, directly and indirectly, support more jobs than the export of any other commodity, according to a study by the U.S. Department of Commerce. Boeing Company, Lockheed Martin Corporation and General Electric Company are some of the most prominent players in this space.
Advertisement
ALLO and
Correlation & Price change
A.I.dvisor indicates that over the last year, ALLO has been loosely correlated with EDIT. These tickers have moved in lockstep 49% of the time. This A.I.-generated data suggests there is some statistical probability that if ALLO jumps, then EDIT could also see price increases.
| Ticker / NAME | Correlation To ALLO | 1D Price Change % | ||
|---|---|---|---|---|
| ALLO | 100% | -3.41% | ||
| EDIT - ALLO | 49% Loosely correlated | -4.99% | ||
| AXON - ALLO | 44% Loosely correlated | +4.26% | ||
| RCKT - ALLO | 43% Loosely correlated | +1.22% | ||
| ARRY - ALLO | 43% Loosely correlated | +9.94% | ||
| FDMT - ALLO | 43% Loosely correlated | +4.25% | ||
More | ||||
AXON and
Correlation & Price change
A.I.dvisor indicates that over the last year, AXON has been loosely correlated with TECH. These tickers have moved in lockstep 61% of the time. This A.I.-generated data suggests there is some statistical probability that if AXON jumps, then TECH could also see price increases.
| Ticker / NAME | Correlation To AXON | 1D Price Change % | ||
|---|---|---|---|---|
| AXON | 100% | +4.26% | ||
| TECH - AXON | 61% Loosely correlated | -0.03% | ||
| VCYT - AXON | 58% Loosely correlated | +4.36% | ||
| BEAM - AXON | 57% Loosely correlated | +2.62% | ||
| SEER - AXON | 56% Loosely correlated | -1.24% | ||
| ADPT - AXON | 56% Loosely correlated | +1.98% | ||
More | ||||
| 1 Day | |||
|---|---|---|---|
| ETFs / NAME | Price $ | Chg $ | Chg % |
| PLTU | 45.59 | 1.86 | +4.25% |
| Direxion Daily PLTR Bull 2X ETF (PLTU) | |||
| VT | 156.71 | 1.77 | +1.14% |
| Vanguard Total World Stock ETF (VT) | |||
| ZAPR | 27.17 | 0.05 | +0.18% |
| Innovator 1 Yr April (ZAPR) | |||
| SHYM | 21.94 | 0.02 | +0.09% |
| iShares Short Duration High Yield Muni Active ETF (SHYM) | |||
| BOXA | 104.58 | N/A | N/A |
| Alpha Architect Aggregate Bond ETF | |||